Vericel Corp (NASDAQ: VCEL) — Research Snapshot as of October 27, 2026

Company Profile (brief)

Vericel is a commercial-stage biopharmaceutical company focused on advanced cell therapies and specialty biologics for the sports medicine and severe burn care markets, headquartered in Cambridge, Massachusetts, and formerly known as Aastrom Biosciences [25], [26]. It markets three U.S. products: MACI (cartilage repair), Epicel (burn skin replacement), and NexoBrid (eschar removal, licensed from MediWound) [3], [24]. The stock trades near ~$43 with a market cap of ~$2.2B and ~51.2M shares; its 52-week range is $28.95–$49.32, with YTD +19.5% and 1-year +18.5% returns [10], [27]. Valuation is rich: a P/E (TTM) of ~92 and forward PE of ~66 [27].

Recent Catalysts (last ~1–3 months)